<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Cibus, an agricultural biotechnology company, has partnered with Biographica, a UK-based AI-focused biotechnology company, to identify gene editing targets for developing disease-resistant traits in oilseed rape and canola crops.
      </p>
    </li>
    <li>
      <p>
        The partners report that Biographica will use its AI and machine learning platform to analyze gene targets associated with disease resistance, while Cibus will apply its crop editing expertise to develop the traits.
      </p>
    </li>
    <li>
      <p>
        The pilot project aims to accelerate the development of crop varieties with improved disease-resistance traits for commercial farming applications.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.manilatimes.net/2024/11/19/tmt-newswire/globenewswire/cibus-and-biographica-announce-collaboration-using-artificial-intelligence-ai-to-advance-disease-resistance-in-canola-and-oilseed-rape/2007216">
      The Manila Times
    </a>
  </p>
</div>


Crop Biotech

PROMINENT_CATEGORY

<div>
 
 <p>Cibus, a biotechnology company specializing in agriculture, has joined forces with Biographica, a UK-based biotech company with a focus on AI, to seek out gene-editing targets. The goal is to develop disease-resistant traits within canola and oilseed rape crops.</p>
 <p>According to the partners, Biographica will employ its AI and machine learning platform for the analysis of gene targets associated with disease resistance. Meanwhile, Cibus will leverage its expertise in crop editing to develop these traits.</p>
 <p>This pilot project has been established with the aim of speeding up the development process for crop strains that have improved disease-resistance traits, intended for commercial farming use.</p>
 
</div>

Cibus partners with Biographica to develop AI-driven disease resistance traits for canola

INCUMBENTS_PRESENT

<div>
 
 <p>The American agricultural chemical and seed company, Corteva, created a novel non-GMO hybrid wheat technology aimed at enhancing wheat production systems and yield improvements. This technology, planned to be launched by 2027 in North America, crosses two genetically different parents to produce more resilient, higher-yielding plants.</p>
 <p>Unlike existing systems for wheat hybridization, Corteva's technology is touted as the first of its kind and tests indicate that it operates effectively in 100% wheat germplasm. This facet of the technology permits quicker genetic gains and commercial-scale seed delivery.</p>
 <p> This innovation can boost yield potential by 10% while using the same amount of resources and land, demonstrate 20% higher yields in water-stressed environments compared to elite varieties, and hasten the market speed of new elite germplasm thanks to increased parent seed production.</p>
 
</div>

Corteva develops non-GMO hybrid wheat technology

ANALYST_QUICK_TAKE

<div>

 <p>Ginkgo Bioworks, a biosecurity and cell programming platform, has reached a significant milestone in its collaboration with US-based biopharmaceutical company, Merck. It has received a research payment of USD 9 million. </p>
 <p>The focus of the partnership is to enhance biologic manufacturing. Both firms are now progressing to the second phase of the collaboration, targeting to improve the production process. </p>
 
</div> <p><b>Analyst QuickTake:<br>
 </b> In <a href="https:<br>
//www.prnewswire.com/news-releases/ginkgo-bioworks-announces-collaboration-with-merck-to-improve-biologic-manufacturing-301893643.html"> August 2023 </a> , Gingko Bioworks partnered with Merck to improve biologic manufacturing efficiency and increase yields by leveraging Ginkgo's expertise in cell engineering, high-throughput screening, and process optimization. Through the partnership, Ginkgo is eligible to receive an aggregate of up to USD 490 million in upfront research fees and payments.</p>

Ginkgo Bioworks and Merck advance partnership to improve biologic manufacturing process

<div>
 
 <p>AcreShield, a company with an AI seed selection platform, managed to raise over USD 2.5 million in a Series A funding round. The leading investor was Vertical Ventures Inc., with InnoVenture Iowa also taking part. There is an authorization for an additional USD 2 million for the Series A round from the board of directors.</p>
 <p>On its use, the company claims the funds will be used to improve AcreShield's AI technology known as the "Yield Optimizer". This technology aims to help farmers by offering them a smarter way for seed selection and ensuring guaranteed ROI performance.</p>
 <p>The "Yield Optimize", according to AcreShield, is the first AI seed selection program in the commercial market that predicts yield using independent data of seed performance. The focus of the company is on solving the "Yield Gap" challenge faced by row crop farmers and is targeting a 180-million-acre market opportunity in the US.</p>
 
</div>

AcreShield raises USD 2.5 million in Series A funding to develop AI seed selection technology

<div>
 
 <p>Lavie Bio, a subsidiary of Evogene Ltd focusing on creating bacterial solutions for plants, has secured a grant from the Israel Innovation Authority. The details of the grant remain undisclosed, yet it is set to aid the progression of Lavie Bio's MicroFermentor technology.</p>
 <p>This patented technology, intended for the delivery of ag-biologicals, is expected to decrease application costs, enhance shelf-life and maintain bacterial viability post-field application. The grant will facilitate its next development phase, moving closer to commercialization.</p>
 
</div>

Lavie Bio receives grant from Israel Innovation Authority to develop MicroFermentor

<div>

 <p>Pairwise, a gene editing startup, has secured USD 40 million in a Series C funding round. The funding was spearheaded by Deerfield Management, and saw participation from Aliment Capital, Leaps by Bayer, and Corteva.</p> 
 <p>The newly raised capital will be directed towards the expansion of Pairwise's product pipeline and the development of its "Fulcrum" suite of gene editing tools. In a concurrent development, Pairwise has entered into a five-year joint venture with Corteva, with the aim of enhancing gene editing technology to improve climate resilience in corn and soy.</p>
 
</div>

Pairwise raises USD 40 million in Series C funding to scale product pipeline

<div>

<p>Agricultural biotechnology firm, Cibus, Inc., has made public its decision to offer shares of Class A common stock in a public offering. The firm is looking to provide underwriters with a 45-day option to acquire up to 15% of the shares offered.</p>
<p>Roth Capital Partners and A.G.P./Alliance Global Partners have been appointed as joint book-running managers for the sale.</p>
<p>The company has plans to devote the net profits from the offering towards the creation of novel seed traits, enhancement of current ones, provision for the operations of Trait Machine, and for meeting working capital requirements and other general corporate necessities.</p>

</div>

Cibus announces proposed public offering of Class A common stock

<div>
 
 <p>A UK AgriTech company called Solasta Bio, which specializes in green insecticides, successfully secured USD 14 million in Series A funding. This round of funding saw leading participation from Forbion, with cooperating leads from FMC Ventures and Corteva Inc. The company also received support from some of its existing investors.</p>
 <p>Solasta Bio plans to use this funding to further advance its technology platform along with developing its pipeline of insect control agents. It also intends to expand its operations in the US and scale up its manufacturing capabilities. Moreover, the company wants to explore strategic opportunities that extend beyond the scope of crop use.  The company has set a goal to make its entry into the market by 2027.</p>
 
</div>

Solasta Bio raises USD 14 million in Series A funding to advance bio-insecticide

<div>
 
 <p>Moolec Science, a plant-based ingredient startup, has revealed plans to harvest its genetically engineered plant products, GLASO™ and Piggy Sooy™, in October 2024. </p>
 <p>GLASO™ is stated to possess 3 times higher gamma-linolenic acid (GLA) content than conventional sources. Piggy Sooy™ could potentially yield pork meat proteins equivalent to 10 pigs per acre.</p>
 <p>The company has indicated its goal is to extend its commercial approach to connect with bigger markets and more customers.</p>
  
</div>

Moolec confirms harvest of its genetically engineered plant-grown products

<div>
 
 <p>Ginkgo Bioworks, a cell programming and biosecurity platform, has announced that it has regained compliance with the NYSE minimum bid price requirement. This occurred after its Class A common stock had a closing bid price at or above USD 1.00 on the last day of August, and the company's 30-day trading average also closed above USD 1.00.</p>
 <p>Previously, on May 7, 2024, Gingko received a Continued Listing Standard Notice from the NYSE. This notice was sent after it failed to comply with the NYSE’s minimum requirement on the average closing price of its Class A common stock.</p>
 
</div>

All Updates

Cibus partners with Biographica to develop AI-driven disease resistance traits for canola

Corteva develops non-GMO hybrid wheat technology

Ginkgo Bioworks and Merck advance partnership to improve biologic manufacturing process

AcreShield raises USD 2.5 million in Series A funding to develop AI seed selection technology

Lavie Bio receives grant from Israel Innovation Authority to develop MicroFermentor

Pairwise raises USD 40 million in Series C funding to scale product pipeline

Cibus announces proposed public offering of Class A common stock

Solasta Bio raises USD 14 million in Series A funding to advance bio-insecticide

Moolec confirms harvest of its genetically engineered plant-grown products

Ginkgo regains compliance with NYSE minimum bid price requirement

Crop Biotech

Cibus partners with Biographica to develop AI-driven disease resistance traits for canola

Contact us